KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2025)

Historic Short term Debt for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to $8.9 million.

  • Recursion Pharmaceuticals' Short term Debt rose 851.69% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 851.69%. This contributed to the annual value of $8.4 million for FY2024, which is 2044878.05% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Short term Debt stood at $8.9 million, which was up 851.69% from $8.8 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Short term Debt peaked at $8.9 million during Q3 2025, and registered a low of $41000.0 during Q4 2023.
  • For the 3-year period, Recursion Pharmaceuticals' Short term Debt averaged around $7.3 million, with its median value being $8.4 million (2024).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Short term Debt surged by 2044878.05% in 2024 and then soared by 792.95% in 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' Short term Debt (Quarter) stood at $41000.0 in 2023, then surged by 20448.78% to $8.4 million in 2024, then rose by 5.86% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $8.8 million for Q2 2025, and $8.6 million during Q1 2025.